IN2014CN04498A - - Google Patents

Download PDF

Info

Publication number
IN2014CN04498A
IN2014CN04498A IN4498CHN2014A IN2014CN04498A IN 2014CN04498 A IN2014CN04498 A IN 2014CN04498A IN 4498CHN2014 A IN4498CHN2014 A IN 4498CHN2014A IN 2014CN04498 A IN2014CN04498 A IN 2014CN04498A
Authority
IN
India
Prior art keywords
domain
sequence
terminus
amino acid
protein
Prior art date
Application number
Other languages
English (en)
Inventor
Jerzy Szczepan Pieczykolan
Sebastian Pawlak
Michal Szymanik
Anna Maria Pieczykolan
Bartlomiej Maciej Zerek
Piotr Rózga
Albert Robert Jaworski
Kaminska Malgorzata Izabela Teska
Original Assignee
Adamed Sp Zoo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adamed Sp Zoo filed Critical Adamed Sp Zoo
Publication of IN2014CN04498A publication Critical patent/IN2014CN04498A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81Protease inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/525Tumour necrosis factor [TNF]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/04Fusion polypeptide containing a localisation/targetting motif containing an ER retention signal such as a C-terminal HDEL motif
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/20Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/50Fusion polypeptide containing protease site
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/55Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
IN4498CHN2014 2011-11-28 2012-11-28 IN2014CN04498A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PL397167A PL397167A1 (pl) 2011-11-28 2011-11-28 Przeciwnowotworowe bialko fuzyjne
PCT/IB2012/056806 WO2013080147A2 (en) 2011-11-28 2012-11-28 Anticancer fusion protein

Publications (1)

Publication Number Publication Date
IN2014CN04498A true IN2014CN04498A (ru) 2015-09-11

Family

ID=47561689

Family Applications (1)

Application Number Title Priority Date Filing Date
IN4498CHN2014 IN2014CN04498A (ru) 2011-11-28 2012-11-28

Country Status (18)

Country Link
US (1) US20150044162A1 (ru)
EP (1) EP2785362A2 (ru)
JP (1) JP2015500228A (ru)
KR (1) KR20140097529A (ru)
CN (1) CN103974711A (ru)
AU (1) AU2012345494A1 (ru)
BR (1) BR112014012808A2 (ru)
CA (1) CA2856480A1 (ru)
EA (1) EA201491049A1 (ru)
HK (1) HK1201727A1 (ru)
IL (1) IL232743A0 (ru)
IN (1) IN2014CN04498A (ru)
MX (1) MX2014006369A (ru)
PH (1) PH12014501083A1 (ru)
PL (1) PL397167A1 (ru)
SG (1) SG11201402312WA (ru)
WO (1) WO2013080147A2 (ru)
ZA (1) ZA201404667B (ru)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6548630B2 (ja) 2013-03-12 2019-07-24 モレキュラー テンプレーツ, インク.Molecular Templates, Inc. 特定の細胞型の選択的死滅のための細胞標的化結合領域と志賀毒素aサブユニット領域とを含む細胞毒性タンパク質
WO2014141094A1 (en) 2013-03-14 2014-09-18 Adamed Sp. Z O.O. Anticancer conjugate
EP3868776A1 (en) 2014-01-27 2021-08-25 Molecular Templates, Inc. Mhc class i epitope delivering polypeptides
ES2864124T3 (es) * 2014-03-11 2021-10-13 Molecular Templates Inc Proteínas que comprenden regiones de unión, regiones efectoras de la subunidad A de toxina Shiga y motivos señal de localización de retículo endoplasmático carboxi terminal
US11142584B2 (en) 2014-03-11 2021-10-12 Molecular Templates, Inc. CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same
ES2717751T3 (es) * 2014-06-11 2019-06-25 Molecular Templates Inc Polipéptidos efectores de la subunidad A de la toxina de Shiga resistentes a la escisión por proteasa y moléculas dirigidas a células que los comprenden
US10392425B2 (en) 2015-02-05 2019-08-27 Molecular Templates, Inc. Multivalent CD20-binding molecules comprising Shiga toxin A subunit effector regions and enriched compositions thereof
US10428132B2 (en) 2015-02-11 2019-10-01 West China Hospital, Sichuan University Tumor necrosis factor-related apoptosis-inducing ligand variant, as well as a preparation method and use thereof
RS60441B1 (sr) * 2015-05-30 2020-07-31 Molecular Templates Inc De-imunizovane, strukture shiga toksin a podjedinice i ciljani ćelijski molekuli koji sadrže isti
CN112574316A (zh) * 2015-07-02 2021-03-30 博际生物医药科技(杭州)有限公司 用于肿瘤靶向治疗的白细胞介素-15融合蛋白
KR101732126B1 (ko) 2015-11-05 2017-05-02 한국생명공학연구원 췌장암 치료용 융합 단백질 및 이의 용도
PL233352B1 (pl) * 2016-09-15 2019-10-31 Adamed Spolka Z Ograniczona Odpowiedzialnoscia Przeciwnowotworowe białko fuzyjne
IL302130A (en) 2016-12-07 2023-06-01 Molecular Templates Inc Shiga toxin A subunit activator polypeptides, Shiga toxin activator scaffolds and cell-targeting molecules for site-specific conjugation
CN106632680A (zh) * 2016-12-27 2017-05-10 上海交通大学 植物体系表达人源化抗agr2单克隆抗体18a4的质粒构建
KR102590672B1 (ko) 2017-01-25 2023-10-18 몰레큘러 템플레이츠, 인코퍼레이션. 탈면역된 시가 독소 a 서브유닛 이펙터 및 cd8+ t-세포 에피토프를 포함하는 세포-표적화 분자
CN112105631A (zh) * 2018-03-06 2020-12-18 约翰霍普金斯大学 Treg耗尽和检查点抑制剂的组合
WO2019204272A1 (en) 2018-04-17 2019-10-24 Molecular Templates, Inc. Her2-targeting molecules comprising de-immunized, shiga toxin a subunit scaffolds
WO2020234498A2 (es) * 2019-05-15 2020-11-26 Universidad De Granada Terapia génica con los genes hokd y ldrb para el tratamiento del cáncer
CN113354738B (zh) * 2020-03-05 2022-09-09 绍兴德方华生物技术有限公司 融合毒素VEGF165b/mGEL及其编码基因与应用
IL300701A (en) * 2020-08-17 2023-04-01 Atb Therapeutics Immunotoxin-containing immunotoxin-containing or renase
CN117384859B (zh) * 2023-12-13 2024-03-22 北京翊博生物集团有限公司 一种树突状细胞来源的外泌体的制备方法及应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4435304B2 (ja) 1995-06-29 2010-03-17 イミュネックス・コーポレーション アポトーシスを誘導するサイトカイン
WO2001060393A1 (en) 2000-02-16 2001-08-23 Bechtel Bwxt Idaho, Llc Selective destruction of cells infected with human immunodeficiency virus
ZA200305980B (en) 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
CN1257187C (zh) * 2003-10-22 2006-05-24 上海恰尔生物技术有限公司 钙网蛋白-肿瘤坏死因子相关凋亡诱导配体的融合蛋白及其制法和用途
CN100549175C (zh) 2003-11-03 2009-10-14 沙东生物药业(天津)有限公司 一种具有抑癌作用的重组蛋白及其编码基因与应用
US7252993B2 (en) 2004-03-12 2007-08-07 Battelle Energy Alliance, Llc Plasmids encoding therapeutic agents
ES2660026T3 (es) 2005-07-29 2018-03-20 The Government Of The United States Of America, As Represented By The Secretary Of Health And Human Services Exotoxinas de pseudomonas mutadas con antigenicidad reducida
ZA200800969B (en) 2005-08-16 2009-08-26 Genentech Inc Apoptosis sensitivity to APO2L/TRAIL by testing for GalNac-T14 expression in cells/tissues
CA2668017A1 (en) 2006-10-30 2008-05-08 Viventia Biotech Inc. Improved conjugates
JP4954293B2 (ja) 2006-12-29 2012-06-13 オスプレイ・ファーマシューティカルズ・ユーエスエイ・インコーポレイテッド 改変毒素を選択および生産する方法、改変毒素を含む複合体、およびそれらの使用
WO2009002947A2 (en) 2007-06-22 2008-12-31 Affymax, Inc. Compounds and peptides that bind the trail receptor
GB0723059D0 (en) 2007-11-23 2008-01-02 Nat Univ Ireland Improved cytokine design
GB0724532D0 (en) 2007-12-17 2008-01-30 Nat Univ Ireland Trail variants for treating cancer
DK2252627T3 (en) * 2008-01-24 2017-08-14 Esperance Pharmaceuticals MERGER CONSTRUCTION WITH LYTIC DOMAIN AND METHOD FOR PRODUCING AND USING SAME.
TW200950778A (en) 2008-05-14 2009-12-16 Genentech Inc Methods of using Apo2L/TRAIL to treat cancer
AU2009269141B2 (en) * 2008-06-30 2013-04-04 University Of Pennsylvania Fn14/TRAIL fusion proteins

Also Published As

Publication number Publication date
EP2785362A2 (en) 2014-10-08
IL232743A0 (en) 2014-07-31
EA201491049A1 (ru) 2014-10-30
JP2015500228A (ja) 2015-01-05
ZA201404667B (en) 2015-09-30
BR112014012808A2 (pt) 2019-09-24
AU2012345494A1 (en) 2014-07-10
CN103974711A (zh) 2014-08-06
MX2014006369A (es) 2014-07-09
WO2013080147A2 (en) 2013-06-06
WO2013080147A3 (en) 2014-02-13
US20150044162A1 (en) 2015-02-12
CA2856480A1 (en) 2013-06-06
KR20140097529A (ko) 2014-08-06
HK1201727A1 (en) 2015-09-11
PL397167A1 (pl) 2013-06-10
SG11201402312WA (en) 2014-06-27
PH12014501083A1 (en) 2014-08-04

Similar Documents

Publication Publication Date Title
IN2014CN04498A (ru)
MX2013007872A (es) Proteina de fusion anticancer.
MX2013006213A (es) Proteina de funsion anticancer.
NZ712148A (en) Wt1 antigen peptide conjugate vaccine
IN2014KN01715A (ru)
UA115436C2 (uk) Протираковий злитий протеїн
MX2012008999A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340015B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX342291B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340016B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
NZ629843A (en) Identification of channelrhodopsin-2 (chop2) mutations and methods of use
BR112017009790A2 (pt) anticorpos direcionados ao anti-ang2 e métodos de uso
EA201990298A1 (ru) Способы и композиции для лечения рака
WO2010011952A3 (en) Flip death effector domain derived peptides for inducing autophagy
WO2012143477A3 (en) Anticancer fusion protein
WO2016007919A3 (en) Antibody fragments for detecting cancer and methods of use
MX2013003168A (es) Anticuerpo contra ephrin b2 y su uso.
MX2017013480A (es) Composicion farmaceutica para tratar y/o prevenir el cancer.
PH12014502198A1 (en) Osteoprotegerin derived composition and use thereof
GB201019467D0 (en) Therapeutic agent
UA108911C2 (xx) Протираковий злитий протеїн
WO2013052168A3 (en) Detection aib1-delta 4 protein
TH139454A (th) การใช้แหล่ง l3และ/หรือ l5 ในฐานะเป็นวัคซีน หรือในเชิงวินิจฉัยสำหรับโรคปรสิต
TH159052A (th) ฟิวชั่นโปรตีนต้านมะเร็ง (Anticancer fusion protein)
TH135824B (th) การบำบัดมะเร็งซึ่งถูกปรับปรุงบนฐานแอนทิเจนซึ่งสัมพันธ์กับเนื้องอกอนุพันธ์จาก ไซคลิน d1